Combining growth factors, stem cells, and gene therapy for the aging brain

被引:22
作者
Behrstock, S [1 ]
Svendsen, CN [1 ]
机构
[1] Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA
来源
STRATEGIES FOR ENGINEERED NEGLIGIBLE SENESCENCE: WHY GENUINE CONTROL OF AGING MAY BE FORESEEABLE | 2004年 / 1019卷
关键词
stem cell; GDNF; Parkinson disease; aging; gene therapy; brain;
D O I
10.1196/annals.1297.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Stem cells have been suggested as a possible "fountain of youth" for replacing tissues lost during aging. In the brain, replacing lost neurons is a challenge, as they have to then be reconnected with their appropriate targets. Perhaps a more realistic and practical strategy for affecting the aging process would be to prevent the loss of neurons from occurring, thus retaining intact circuitry. Glial cell line-derived neurotrophic factor (GDNF) can reverse some aspects of aging in the monkey. Additionally, we have recently shown that GDNF directly infused into the human brain has significant effects on the symptoms of Parkinson disease. Human neural stem cells can be cultured, genetically modified, and transplanted. As such, these cells are ideal for ex vivo gene therapy, and may be used in the future as "minipumps" to release GDNF in vivo to protect aging neurons. Using such an approach could delay the effects of aging in the brain, giving a better quality of life. Stem cells might not be the fountain of youth, but provide a fountain of youth through the release of growth factors such as GDNF.
引用
收藏
页码:5 / 14
页数:10
相关论文
共 34 条
[11]   Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector [J].
Georgievska, B ;
Kirik, D ;
Rosenblad, C ;
Lundberg, C ;
Björklund, A .
NEUROREPORT, 2002, 13 (01) :75-82
[12]   Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer [J].
Georgievska, B ;
Kirik, D ;
Björklund, A .
EXPERIMENTAL NEUROLOGY, 2002, 177 (02) :461-474
[13]   Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease [J].
Gill, SS ;
Patel, NK ;
Hotton, GR ;
O'Sullivan, K ;
McCarter, R ;
Bunnage, M ;
Brooks, DJ ;
Svendsen, CN ;
Heywood, P .
NATURE MEDICINE, 2003, 9 (05) :589-595
[14]  
Grondin R, 2003, J NEUROSCI, V23, P1974
[15]   Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys [J].
Grondin, R ;
Zhang, ZM ;
Yi, A ;
Cass, WA ;
Maswood, N ;
Andersen, AH ;
Elsberry, DD ;
Klein, MC ;
Gerhardt, GA ;
Gash, DM .
BRAIN, 2002, 125 :2191-2201
[16]  
Hebert MA, 1997, J PHARMACOL EXP THER, V282, P760
[17]   Gene therapy - Seeking the cause of induced leukemias in X-SCID trial [J].
Kaiser, J .
SCIENCE, 2003, 299 (5606) :495-495
[18]   Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor [J].
Kirik, D ;
Rosenblad, C ;
Björklund, A .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (11) :3871-3882
[19]   Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease [J].
Kirik, D ;
Georgievska, B ;
Rosenblad, C ;
Björklund, A .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 13 (08) :1589-1599
[20]   Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease [J].
Kordower, JH ;
Emborg, ME ;
Bloch, J ;
Ma, SY ;
Chu, YP ;
Leventhal, L ;
McBride, J ;
Chen, EY ;
Palfi, S ;
Roitberg, BZ ;
Brown, WD ;
Holden, JE ;
Pyzalski, R ;
Taylor, MD ;
Carvey, P ;
Ling, ZD ;
Trono, D ;
Hantraye, P ;
Déglon, N ;
Aebischer, P .
SCIENCE, 2000, 290 (5492) :767-773